These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 9636449

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
    Marcus N, Khaghani A, Burke M, Yacoub M, Banner N.
    Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460
    [No Abstract] [Full Text] [Related]

  • 3. Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study.
    Opelz G.
    Transplant Proc; 1997 Jun; 29(1-2):617-9. PubMed ID: 9123156
    [No Abstract] [Full Text] [Related]

  • 4. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
    Bruce DS, Newell KA, Woodle ES, Millis JM, Piper JB, Huss E, Thistlethwaite JR.
    Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
    [No Abstract] [Full Text] [Related]

  • 5. Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients.
    Seydoux C, Stumpe F, Hurni M, Ruchat P, Fischer A, Mueller X, von Segesser L, Goy JJ.
    Transplant Proc; 1998 Dec; 30(8):4037-43. PubMed ID: 9865288
    [No Abstract] [Full Text] [Related]

  • 6. Early cyclosporine blood levels impact the incidence of acute rejection and overall mortality in the first year after heart transplantation.
    Gómez-Sánchez MA, Delgado JF, Escribano P, Santos M, Sotelo T, Gil R, Hernández-Afonso J, Ortuño B, Romero F, Sáenz de la Calzada C, Rodriguez JE, Rufilanchas JJ.
    Transplant Proc; 1998 Aug; 30(5):1671-2. PubMed ID: 9723237
    [No Abstract] [Full Text] [Related]

  • 7. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
    Fabrega AJ, Corwin CL, Hunsicker L.
    Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
    [No Abstract] [Full Text] [Related]

  • 8. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
    Lange D, Bechstein WO, Blumhardt G, Lemmens P, Schattenfroh N, Neuhaus P.
    Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
    [No Abstract] [Full Text] [Related]

  • 9. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
    Hanrahan JS, Ibrahim H, Tolman D, Kirchberg D, Salter D, Guerraty A, Mohanty PK.
    Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
    [No Abstract] [Full Text] [Related]

  • 10. Impact of cyclosporine dose on long-term outcome after heart transplantation.
    Valantine H, Hunt S, Gamberg P, Miller J, Luikart H.
    Transplant Proc; 1994 Oct; 26(5):2710-2. PubMed ID: 7940848
    [No Abstract] [Full Text] [Related]

  • 11. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study.
    Opelz G.
    Transplant Proc; 1997 Oct; 29(1-2):73-6. PubMed ID: 9123162
    [No Abstract] [Full Text] [Related]

  • 12. Adjuncts to triple-drug therapy after cardiac transplantation: a comparison of Nashville rabbit antithymocyte serum to OKT3.
    Aziz S, Kruse AP, Roby PV, Allen MD, Khan K, Fishbein D.
    Transplant Proc; 1994 Oct; 26(5):2721-3. PubMed ID: 7940852
    [No Abstract] [Full Text] [Related]

  • 13. Cyclosporine-based steroid-free therapy in pediatric heart transplantation: long-term results.
    Livi U, Caforio AL, Gambino A, Tursi V, Milanesi O, Stellin G, Angelini A, Casarotto D.
    Transplant Proc; 1998 Aug; 30(5):1975-6. PubMed ID: 9723358
    [No Abstract] [Full Text] [Related]

  • 14. Induction of immunosuppression with OKT3 following heart transplantation: kidney function as a criterion for control of protocol duration.
    Rodríguez JA, Crespo-Leiro MG, Paniagua MJ, Muñiz J, Hermida LF, Fojón S, Cuenca JJ, Juffé-Stein A, Castro-Beiras A.
    Transplant Proc; 1999 Sep; 31(6):2517-8. PubMed ID: 10500696
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO, Feehally J, Scriven SD, Veitch PS, Bell PR.
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract] [Full Text] [Related]

  • 16. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K, Irie A, Mashimo S, Endo T, Koshiba K.
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract] [Full Text] [Related]

  • 17. Acute cardiac ongoing rejection: comparison between different strategies.
    Forni A, Faggian G, Luciani GB, Lamascese N, Mazzucco A.
    Transplant Proc; 2001 May; 33(3):2395-7. PubMed ID: 11377573
    [No Abstract] [Full Text] [Related]

  • 18. Hepatitis B and C virus-induced diseases and acute rejection after liver transplantation.
    Maggi U, Rossi G, Vannelli A, Caccamo L, Gatti S, Paone G, Reggiani P, Melada E, Latham L, Andreani P, Fassati LR.
    Transplant Proc; 1998 Dec; 30(8):3946-7. PubMed ID: 9865255
    [No Abstract] [Full Text] [Related]

  • 19. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation.
    Johnson MR, Mullen GM, O'Sullivan EJ, Liao Y, Heroux AL, Kao W, Pifarre R, Costanzo-Nordin MR.
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1149-51. PubMed ID: 8442068
    [Abstract] [Full Text] [Related]

  • 20. Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation.
    Taylor DO, Kfoury AG, Pisani B, Hammond EH, Renlund DG.
    Transplant Proc; 1997 Dec; 29(8A):13S-15S. PubMed ID: 9414668
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.